日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Osimertinib with or without savolitinib as first-line treatment for MET-aberrant, EGFR-mutant NSCLC: randomized phase 2 trial (FLOWERS)

奥希替尼联合或不联合沙沃替尼作为MET异常、EGFR突变型非小细胞肺癌的一线治疗:随机2期试验(FLOWERS)

Li, Anna; Feng, Wei-Neng; Li, Juan; Xu, Bing-Fei; Zhao, Jun; Jia, Yun; Tang, Ke-Jing; Li, Yong-Sheng; Zhou, Cheng-Zhi; Fan, Yun; Xu, Chong-Rui; Sun, Yue-Li; Chen, Hua-Jun; Yan, Hong-Hong; Shi, Zong-Kun; Yang, Jin-Ji

Neoadjuvant chemotherapy-enabled tumor conversion and surgical resection in pediatric primary pulmonary Ewing sarcoma: a case report

新辅助化疗促进儿童原发性肺尤文氏肉瘤肿瘤转化及手术切除:病例报告

Lin, Jun-Ping; Li, Chong-Rui; Li, Bin; Yang, Jian-Bao

Multiple Primary Lung Cancer With Driver Gene Mutations: Is Targeted Therapy Always the Optimal Choice?-A Case Report

伴有驱动基因突变的多原发性肺癌:靶向治疗总是最佳选择吗?——病例报告

Ren, Zi-Rui; Wu, Lv; Lu, Chang; Wang, Fen; Peng, Ying-Long; Cai, Dong-Xuan; Tang, Li-Bo; Li, Jia-Ting; Guo, Zhi; Chen, Zhi-Hong; Deng, Yu; Sun, Lu; Wei, Xue-Wu; Huang, Qian-Lin; Xu, Chong-Rui; Zhou, Qing

A phase II trial of anlotinib plus EGFR-TKIs in advanced non-small cell lung cancer with gradual, oligo, or potential progression after EGFR-TKIs treatment (CTONG-1803/ALTER-L001)

一项针对接受 EGFR-TKI 治疗后出现渐进性、寡转移性或潜在进展的晚期非小细胞肺癌患者的 II 期试验,评估安罗替尼联合 EGFR-TKI 的疗效 (CTONG-1803/ALTER-L001)

Chen, Hua-Jun; Tu, Hai-Yan; Hu, Yanping; Fan, Yun; Wu, Guowu; Cang, Shundong; Yang, Yi; Yang, Nong; Ma, Rui; Jin, Gaowa; Xu, Ximing; Liu, Anwen; Tang, Shubin; Cheng, Ying; Yu, Yan; Xu, Chong-Rui; Zhou, Qing; Wu, Yi-Long

Multiple ctDNA- based biomarkers predict benefit from selective RET Inhibition in non-small cell lung cancer patients: exploratory analysis of a prospective study

多种基于ctDNA的生物标志物可预测非小细胞肺癌患者从选择性RET抑制治疗中获益:一项前瞻性研究的探索性分析

Lu, Chang; Xu, Chong-Rui; Zhang, Yi-Chen; Ke, E-E; Sun, Yue-Li; Bai, Xiao-Yan; Chen, Zhi-Hong; Su, Jian; Deng, Yu; Hou, Ting; Zhao, Fei; Li, Min; Wang, Bin-Chao; Tu, Hai-Yan; Wang, Zhen; Zhang, Xu-Chao; Chen, Hua-Jun; Yang, Jin-Ji; Zhong, Wen-Zhao; Zhou, Qing; Wu, Yi-Long

Cellular dynamics in cerebrospinal fluid unveils the key regulators of intracranial response to immune checkpoint inhibitors in NSCLC brain metastases

脑脊液细胞动力学揭示了非小细胞肺癌脑转移中颅内免疫检查点抑制剂反应的关键调节因子

Li, Yang-Si; Lai, Wenpu; Yin, Kai; Tu, Hai-Yan; Li, Liang; Lin, Shou-Heng; Li, Peng; Zhou, De-Xiang; Guo, Wei-Bang; Yang, Jin-Ji; Zhou, Qing; Zhong, Wen-Zhao; Zhang, Xu-Chao; Jiang, Ben-Yuan; Wang, Zhen; Yang, Xue-Ning; Wang, Bin-Chao; Pan, Yi; Chen, Hua-Jun; Xu, Chong-Rui; Zeng, Lu; Chen, Zhi-Hong; Yan, Hong-Hong; Sun, Hao; Dong, Zhong-Yi; Liu, Si-Yang Maggie; Li, Yangqiu; Luo, Oscar Junhong; Zheng, Mei-Mei; Wu, Yi-Long

Clinical and dynamic circulating cytokines profile features of long-term progression-free survival benefit to immune checkpoint inhibitors in advanced non-small cell lung cancer

临床和动态循环细胞因子谱特征与晚期非小细胞肺癌患者接受免疫检查点抑制剂治疗后长期无进展生存期获益相关

Deng, Jia-Yi; Gao, Ming; Fan, Xue; Yan, Hong-Hong; Luo, Wei-Chi; Yang, Ming-Yi; Yang, Xiao-Rong; Chen, Zhi-Hong; Xu, Chong-Rui; Zhou, Qing

Partial response to lorlatinib in thoracic inflammatory myofibroblastic tumor harboring complex and rare ALK fusions: a case report

一例携带复杂罕见ALK融合基因的胸腔炎性肌纤维母细胞瘤患者对劳拉替尼治疗有部分反应:病例报告

Tang, Li-Bo; Peng, Ying-Long; Yang, Xiao-Rong; Li, Jia-Ting; Lu, Chang; Zheng, Mei-Mei; Sun, Lu; Yang, Zheng; Yan, Li-Xu; Deng, Yu; Chen, Zhi-Hong; Lv, Si-Di; Zhou, Qing; Xu, Chong-Rui

Causal relationship between oral/gut microbiota and lung cancer: a two-sample Mendelian randomization study

口腔/肠道菌群与肺癌的因果关系:一项双样本孟德尔随机化研究

Huang, Zi-Jian; Wu, Lv; Peng, Ying-Long; Chen, Zhi-Hong; Xu, Chong-Rui; Deng, Yu; Yan, Hong-Hong; Lu, Chang; Zhou, Qing

Neoadjuvant immunochemotherapy in locally advanced esophageal squamous cell carcinoma: a retrospective study with 2-year survival analysis

局部晚期食管鳞状细胞癌新辅助免疫化疗:一项回顾性研究及2年生存分析

Li, Chong-Rui; Chen, Yu-Zhen; Li, Bin; Ren, Mei-Yu; Meng, Yu-Qi; Song, Tie-Niu; Yang, Jian-Bao; Wang, Cheng; Wei, Xiao-Ping; Jiang, Peng; Zhu, Duo-Jie